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ABSTRACT
Introduction: Type 1 diabetes (T1D) is caused by
autoimmune destruction of the insulin-producing β
cells in the pancreatic islets, leading to insulinopenia
and hyperglycaemia. Genetic analyses indicate that
alterations of the interleukin-2 (IL-2) pathway
mediating immune activation and tolerance predispose
to T1D, specifically the polymorphic expression of the
IL-2 receptor-α chain (CD25) on T lymphocytes.
Replacement of physiological doses of IL-2 could
restore self-tolerance and prevent further autoimmunity
by enhancing the function of CD4+ T regulatory cells
(Tregs) to limit the activation of auto reactive T effector
cells (Teffs). In this experimental medicine study, we
use an adaptive trial design to determine the optimal
dosing regimen for IL-2 to improve Treg function
while limiting activation of Teffs in participants with
T1D.
Methods and analysis: The Adaptive study of IL-2
dose frequency on Tregs in type 1 diabetes
(DILfrequency) is a mechanistic, non-randomised,
repeat dose open-label, response-adaptive study of 36
participants with T1D. The objective is to establish the
optimal dose and frequency of ultra-low dose IL-2: to
increase Treg frequency within the physiological range,
to increase CD25 expression on Tregs, without
increasing CD4+ Teffs. DILfrequency has an initial
learning phase where 12 participants are allocated to
six different doses and frequencies followed by an
interim statistical analysis. After analysis of the learning
phase, the Dose and Frequency Committee will select
the optimal targets for Treg frequency, Treg CD25
expression and Teff frequency. Three groups of eight
participants will be treated consecutively in the
confirming phase. Each dose and frequency selected
will be based on statistical analysis of all data collected
from the previous groups.
Ethics: Ethical approval for DILfrequency was granted
on 12 August 2014.
Results: The results of this study will be reported,
through peer-reviewed journals, conference
presentations and an internal organisational report.
Trial registration numbers: NCT02265809,
ISRCTN40319192, CRN17571.
INTRODUCTION
Type 1 diabetes (T1D) is caused by a loss of
tolerance of the immune system (auto-
immunity) to the body’s own insulin-
producing β cells of the pancreas, leading to
their dysfunction and/or destruction result-
ing in insulin deﬁciency and hypergly-
caemia.1 Autoreactive effector T lymphocytes
(Teffs) are central to disease pathogenesis
and it is thought that many cases of T1D are
caused by poor regulation of Teffs by CD4+
FOXP3+ T regulatory cells (Tregs).2 The
degree of β-cell destruction and insulin deﬁ-
ciency depends on the age of patients at
diagnosis and the duration of their disease.
Children diagnosed under age ﬁve usually
progress rapidly and completely lose their
Strengths and limitations of this study
▸ This is an experimental medicine response-
adaptive study that is statistically designed to
analyse three coprimary immunological end
points to efficiently determine the optimal dose-
frequency ultra-low dose interleukin-2 (IL-2) in
type 1 diabetes (T1D).
▸ The study will investigate the effects of repeated
doses of ultra-low dose IL-2 on the immune
system of participants with T1D.
▸ The mechanism of action of ultra-low dose IL-2
will be characterised in T1D prior to considering
larger phase II/III clinical trials.
▸ The study is not designed to test the efficacy of
ultra-low dose IL-2 treatment in T1D.
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ability to make insulin, whereas those diagnosed as ado-
lescents or adults may preserve a low level of insulin pro-
duction for decades.3 Enhancing β-cell survival and
function is a key goal of T1D immunotherapy because
preservation of even small amounts of endogenous
insulin production can reduce the requirement for
exogenous insulin, a potentially dangerous drug. In add-
ition preservation of a limited β-cell function can
improve glucose metabolism, reduce harmful glycosyla-
tion of proteins in the body, protect against hypogly-
caemia and prevent microvascular complications such as
retinopathy, nephropathy and neuropathy in the long
term.4–6a
The interleukin-2 (IL-2) pathway is one of the most
important genetically validated pathways with thera-
peutic relevance to T1D.7 IL-2 signalling via the high-
afﬁnity, heterotrimeric IL-2 receptor which comprises
CD25 (α chain), CD122 (β) and CD132 (γ), is essential
for the development and maintenance of Tregs that
sustain self-tolerance and prevent autoimmunity.8
Genome-wide association studies have identiﬁed several
genes in the IL-2 pathway (eg, IL2RA encoding CD25,
PTPN2, IL2-IL21 and BACH2) that are associated with an
increased risk of developing T1D.9 Rare monogenic dis-
orders in either FOXP3 (a transcription factor that drives
CD25 expression and the suppressive function of Tregs)
or mutations in the CD25 gene (IL2RA) itself, cause
severe autoimmune syndromes including T1D.10 10a
Analysis and phenotyping of T cells from patients and
controls with variations in IL2RA showed that reduced
CD25 expression on T cells is associated with susceptibil-
ity to T1D.11–13 Other defects in the IL-2 signalling
pathway in Tregs affecting pSTAT511 14 and FOXP315
can also reduce self-tolerance to β cells. Tregs are prefer-
entially activated by IL-2 because they constitutively
express 10-fold higher levels of the heterotrimeric high-
afﬁnity IL-2 receptor than Teffs. The higher sensitivity of
Tregs for IL-2 provides a potential ‘therapeutic window’
where it might be possible to administer ultra-low doses
of IL-2 in order to promote Treg function without stimu-
lating a potentially unfavourable Teff response. Ultra-low
dose IL-2 is amenable to pharmaceutical intervention
owing to the availability of human recombinant IL-2,
(Proleukin, also called Aldesleukin, manufactured by
Novartis Pharmaceuticals UK, Limited; https://www.
medicines.org.uk/emc/medicine/19322) which has
extensive human safety data available. Proleukin has
been used for the treatment of cancer and more recently,
in trials for the treatment of the inﬂammatory disor-
ders graft-versus-host-disease16 17 and hepatitis C induced
vasculitis.18
We are implementing an innovative, experimental
medicine strategy to deliver immunotherapy that sys-
tematically targets the key aetiological pathways in
T1D.7 19 20 DILfrequency and its forerunner, ‘Adaptive
study of IL-2 dose on regulatory T cells in type 1 dia-
betes’ (DILT1D)20 21 are speciﬁcally designed to analyse
the effects of Proleukin on the human peripheral
immune system in blood to establish the dose and fre-
quency of administration required to preferentially
enhance Tregs over Teffs. DILT1D was designed to esti-
mate the single dose of Proleukin required to increase
the frequency of Tregs by a minimum of 10% and a
maximum of 20% over baseline. DILT1D also included a
detailed, mechanistic analysis of the effects of Proleukin
on the whole immune system, in particular any activa-
tion of the Teff arm of the immune system was investi-
gated. DILT1D is completed and the analyses are
ongoing with the results being prepared for publication.
We have used the available data to determine the initial
doses to be used in the learning phase of DILfrequency.
The goal of DILfrequency is to ﬁnd the optimal dose
and frequency of subcutaneous Proleukin that speciﬁcally
increases Treg frequency, and the amount of CD25 on
Tregs, without expanding the Teff population in par-
ticipants with T1D. There is an urgent need for this
information because previous trials of Proleukin in inﬂam-
matory diseases16–18 and in T1D22–26 have used relatively
high doses of Proleukin. These high doses of Proleukin
that were administered in these studies as in induction pro-
tocols have a greater potential to activate Teffs. In addition,
the very large increases of Tregs observed in these trials
were far beyond the physiological range and could lead to
immunosuppression and increased susceptibility to infec-
tions16–18 22–26. In contrast, our aim is to deliver optimal
amounts of Proleukin at a precisely determined frequency
that is immunomodulatory to T cells to restore the T1D
immune system to a healthy homeostatic Teff-Treg rela-
tionship. Previously, the frequency of Proleukin dosing has
been empirically derived from clinical experience of high-
dose Proleukin as immunotherapy for metastatic renal cell
carcinoma27 and HIV infection.28 We now know that these
high doses of Proleukin given in ‘on then off’ treatment
cycles are more suitable for cancer treatment to activate
Teffs and are not optimal for preserving insulin secretion
and treating T1D. Results from a recent trial29 giving T1D
participants Rapamycin with 4.5×106 IU of Proleukin three
times a week for a month was terminated prematurely
because β-cell function was impaired. Rapamycin is used
routinely for immunosuppression in pancreatic islet trans-
plantation and therefore, the observed decline in β-cell
function could be due to the high dose of Proleukin acti-
vating Teffs. Alternatively, Proleukin may have altered the
effects of Rapamycin on β cells.
In DILT1D and DILfrequency we are taking a differ-
ent approach: by using all of the data generated in the
studies together with statistical modelling we aim to ﬁnd
the optimal dose and dosing-schedule for the future
administration of Proleukin to attempt to preserve β-cell
function in newly diagnosed participants with T1D.21
METHODS
Study design
DILfrequency is a mechanistic, non-randomised, repeat
dose, open-label, response-adaptive study of Proleukin,
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recombinant IL-2 (Aldesleukin; Marketing Authorisation
Holder: Novartis Pharmaceuticals UK Limited). This is a
single centre study located at the National Institute for
Health Research/Wellcome Trust Cambridge Clinical
Research Facility, Addenbrooke’s Hospital and the
University of Cambridge Clinical School. The
co-ordination of the study will be carried out by the
National Institute for Health Research Cambridge
Clinical Trials Unit, Cambridge University Hospitals
NHS Foundation Trust.
Thirty-six participants with T1D will be included in
the study. Participants will be enrolled into
DILfrequency for approximately 10–18 weeks depending
on the duration of their treatment. Every participant has
12 visits beginning with a screening visit followed by a
treatment period of 10 visits and a follow-up visit
approximately 4 weeks after the ﬁnal dose of drug
(ﬁgure 1). The trial starts with a learning phase followed
by three groups of participants in a tripartite conﬁrming
phase. The groups are sequentially analysed, so that data
from all of the preceding participants informs the next
group. The expected duration of DILfrequency is
2 years and the clinical part of the study will end when
the last participant attends the last follow-up visit.
Study participants: consent procedure and recruitment
Eligible participants will have a history of T1D and be
less than 60 months from diagnosis (box 1). Potential
participants will be ineligible if they have a history of
severe organ dysfunction, malignancy, active clinical
infection, active autoimmune hyperthyroid or hypothy-
roidism and a donation of more than 500 mL of blood
in the 2 months prior to treatment box 2. Eligible poten-
tial participants that are interested in the study will be
Figure 1 Study design of the learning phase of DILfrequency. The study has 12 visits and starts with a screening visit followed
by a treatment period of 10 visits and a follow-up visit that will be carried out approximately 4 weeks after the final dose of
Proleukin. Twelve participants will be allocated in the learning phase to two different doses and four frequencies of administration
of Proleukin to measure the change from baseline of CD4+ T regulatory cells (Tregs), CD4+ T effectors and CD25 expression on
Tregs during treatment with ultra-low dose interleukin-2. At the first two dosing visits, 90 min time points are measured to access
early immune activation and the effects of repeat dosing on these events.
Box 1 Inclusion criteria
Type 1 diabetes
18–70 years of age
Duration of diabetes less than 60 months from diagnosis
Written and informed consent to participate
Box 2 Eligibility criteria
Hypersensitivity to Proleukin or any excipients
History of severe cardiac disease
History of malignancy within the past 5 years (with the exception
of localised carcinoma of the skin that had been resected for cure
or cervical carcinoma in situ)
History or current use of immunosuppressive agents or steroids
History of unstable diabetes with recurrent hypoglycaemia
History of live vaccination 2 weeks prior to first treatment
Active autoimmune hyperthyroidism or hypothyroidism
Active clinical infection
Major pre-existing organ dysfunction or previous organ allograft
Females who are pregnant, lactating or intend to get pregnant
during the study
Males who intend to father a pregnancy during the study
Donation of more than 500 mL of blood within 2 months prior to
Proleukin administration
Participation in a previous therapeutic clinical trial within 2
months prior to Proleukin administration
Abnormal ECG
Abnormal full-blood count,
Chronic renal failure (stage 3, 4 or 5) and/or evidence of severely
impaired liver function
Alanine transaminase or aspartate transaminase >3× upper limit
of normal (ULN) at screening;
Alkaline phosphatase and bilirubin 2× ULN at screening (isolated
bilirubin >2× ULN is acceptable if bilirubin is fractionated and
direct bilirubin <35% is measured).
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provided with a patient information sheet and a consent
form to review. They will then be contacted by the study
team to determine if they remain interested in partici-
pating in the study or have any further queries.
Interested potential participants will be invited to attend
for an appointment where the chief investigator (CI) or
his delegate will discuss the study with the participant,
who will then provide written informed consent before
undergoing any trial-related procedures.
To maximise participation in DILfrequency we will
deploy the active internet recruitment strategy that
was successfully established for DILT1D.30 Details of
DILfrequency will be posted on http://www.clinical-
trials-type1-diabetes.com/ with updates for participant
engagement posted on https://www.facebook.com/
ClinicalTrialsType1Diabetes and tweeted on https://
twitter.com/t1diabetestrial. Interested potential partici-
pants may then directly contact the study team to discuss
the study. Treating physicians, diabetes nurses and
research nurses may identify potential participants and
with permission, forward the patient’s contact details to
the study team. The study team will also contact poten-
tial participants who have already registered an interest
in taking part in a clinical trial by enrolling in the
ADDRESS-2 register,31 the D-GAP32 or DILT1D20 studies.
A formal recruitment analysis has been speciﬁed as an
exploratory end point in DILfrequency using the meth-
odology developed for DILT1D.30
Coprimary end points
The coprimary end points will be calculated from the
change from baseline measurements and the average of
the last three trough values where: the three coprimary
end points are the frequency of Tregs, CD25 expression
on Tregs and the frequency of Teffs. Baseline measure-
ments are taken at visit two prior to drug administration
and trough values are those obtained immediately
before drug is administered representing the constant,
lowest level observed assuming that a steady state has
been achieved.
The number of Tregs and Teffs and CD25 expression
on Tregs are deﬁned within the CD3+CD4+ ﬂuorescence-
activated cell sorting (FACS) gate (ﬁgure 2).
▸ Tregs % CD25highCD127low within the CD3+CD4+
gate
▸ CD25 expression on Tregs is deﬁned as the mean
ﬂuorescence intensity (MFI) of CD25 allophycocyanin
(APC) within the Treg (CD3+CD4+CD25highCD127low)
gate.
▸ Teff populations (non-Tregs) account for all the
other CD3+CD4+ cells that are not deﬁned as Tregs
within the CD3+CD4+ gate:
– Effector memory % CD45RA−CD62L−
– Central memory % CD45RA−CD62L+
– Naïve Teffs % CD45RA+CD62L+
– Effector memory RA+ (TEMRA) CD45RA+CD62L−
– Central memory %+ Effector memory % = Total
Memory effectors %
– Change in the ratio Naïve effectors %:Total Memory
effectors % deﬁnes the Teff primary end point.
The FACS assay used to measure the three primary
end points will be carried out according to good labora-
tory practice at the Clinical Immunology Laboratory,
Department of Immunology, Addenbrooke’s Hospital,
Cambridge, which is an MHRA accredited laboratory for
Good Clinical Practice.
Secondary end points
▸ Change in Treg frequency, phenotype and prolifer-
ation will be measured by FACS at baseline, during
and following treatment with Proleukin.
▸ Change in Teff frequency, phenotype and prolifer-
ation will be measured by FACS at baseline, during
and following treatment with Proleukin.
▸ Change in natural killer (NK) cell frequency, pheno-
type and proliferation will be measured by FACS at
baseline, during and following treatment with
Proleukin.
▸ Change in B lymphocyte cell frequency, phenotype
and proliferation will be measured by FACS at base-
line, during and following treatment with Proleukin.
▸ Change in T and NK cell intracellular signalling will
be measured by FACS at baseline, during and follow-
ing treatment with Proleukin.
▸ Change in full-blood count will be measured by auto-
matic analyser at baseline, during and following treat-
ment with Proleukin.
▸ Change in plasma/serum levels of IL-2, IL-6, IL-10
and tumour necrosis factor α will be measured by
ELISA.
▸ Change in metabolic control will be measured by
self-monitoring of blood glucose and insulin use;
glycated haemoglobin (HbA1c), C-peptide and
autoantibody status will be clinically measured and
recorded.
The values for the end points will be measured
during the treatment period and followed for 4 weeks
after the last dose for each participant.
Exploratory end points
▸ Genotype of T1D-associated loci in DNA extracted
from blood of participants.
▸ Gene expression and epigenetic analysis of puriﬁed
lymphocyte subsets.
▸ IL-2 sensitivity of Tregs, Teffs and NK subsets in cryo-
preserved peripheral blood mononuclear cells
(PBMCs).
▸ Treg suppression and T effector proliferation assays
on cryopreserved PBMCs.
▸ Antigen speciﬁc T cell assays on cryopreserved
PBMCs.
▸ Sysmex® analysis of whole blood.
▸ Serum/plasma levels of cytokines, soluble receptors
and inﬂammatory markers.
▸ Serum/plasma and cellular metabolites.
▸ Recruitment analysis.
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Safety assessments
Safety and tolerability will be accessed by clinical history,
physical examination, temperature, blood pressure,
heart rate, 12-lead ECGs, clinical laboratory tests and
adverse event recording.
Treatment assignment and monitoring of administration
At the start of the study in the learning phase the ﬁrst
12 participants will be allocated the doses and frequen-
cies (table 1) that are at the extremes of the available
combinations. Group 1 will start treatment ﬁrst, followed
sequentially by groups 2–4. A multivariate model of the
joint distribution of the end points (Tregs, Teffs and
CD25 on Tregs) will be developed as a function of dose
and frequency and the target ranges for each of the
three primary end points will be determined at the ﬁrst
interim analysis meeting. The probability that each
dose/dose-frequency achieves its target will be estimated.
The Dose and Frequency Committee (DFC) will deter-
mine the rules that govern the optimal dose and dose
frequency of Proleukin to be given to participants in the
next group. Based on ongoing analyses of the results
from our single dose study of Proleukin, DILT1D, the
maximum dose of Proleukin that will be assigned is
0.6×106 IU/m2/day because doses above this level may
activate Teffs. The doses and frequencies selected for
participants in the conﬁrming phase are allowed to be
different to those used in the learning phase.
The ﬁrst dose of Proleukin will be administered sub-
cutaneously by participants at the study site following
instruction by an appropriately trained delegated
member of the trial team. Further doses may then be
self-administered by participants or an appropriately
qualiﬁed member of the study team depending on
Figure 2 Clinical fluorescence-activated cell sorting (FACS) assays on whole blood to measure absolute lymphocyte counts,
proportions of lymphocytes and CD25 on T regulatory cells. Fluorescently labelled beads are added to whole blood and analysed
to accurately count the absolute number of lymphocytes (A), beads (B), CD3+ T cells (C) CD4+ and CD8+ T cells (D) CD19+ B
cells and CD19−, CD16+, CD56+ NK cells as a percentage of all lymphocytes (E). In a parallel whole blood FACS assay, a
lymphocyte gate is drawn to include all events (F) and doublets are excluded (not shown). The CD3+, CD4+ T-cell gate excludes
CD8+ T cells and B cells (G). CD127−, CD25+ T regulatory cells (Tregs) are separated from non-Tregs since the non-Tregs are
heterogeneous for CD127 and CD25 and this percentage is used to calculate the absolute Treg count out of CD4+ (H), naïve,
effector memory, central memory and total effector memory CD45 RA+(TEMRA) Tregs (I) and non-Tregs ( J) are measured
according to CD62L and CD45RA expression, as shown. A cocktail of six standardised beads labelled with different amounts of
fluorescent allophycocyanin (APC) are measured by FACS daily to accurately measure CD25-APC on the surface of Tregs (K)
and a standard curve plotted (L). The mean fluorescence intensity of CD25+ on Tregs can be accurately read from the curve,
minimising interassay variation.
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participant preference. The date and time of each dose
administered will be recorded in the source documents.
In the community, the date and time of each dose admi-
nistered will be recorded in the participant’s study diary
that will become part of the source documents. The
study diary, injection sites and count of unused medica-
tion will be carried out at each study visit while on treat-
ment to conﬁrm compliance.
Dose and Frequency Committee and study governance
The role of the DFC is to provide decisions regarding
the choice of dose and frequency of Proleukin to admin-
ister to participants in the conﬁrming phases (groups 5,
6 and 7). After each group has completed its dosing
schedule the data with be extracted from the
DILfrequency OpenClinica database. The data will be
delivered to the DFC within two working days of that
date. The data will include assessments of safety, dose
and dose-frequencies assigned for all participants to that
time point and Teff and Treg frequencies and CD25
expression on Tregs, collated from all visits.
The DFC will make the following decisions:
▸ A safety assessment will be made by a clinician;
▸ Determine if steady state has been achieved for each
participant;
▸ Deﬁne the numerical targets for Treg increase,
increased CD25 expression on Tregs and a minimal
increase in Teffs at the ﬁrst DFC;
▸ Deﬁne the dose and dose-frequencies for the next
group of participants.
The DILfrequency statisticians are responsible for pre-
paring the DFC report that will include:
▸ Plots of all the participant proﬁles (Treg, CD25, Teff
response vs time);
▸ Plots of the sequence of doses and dose intervals;
▸ Scatter plots of the coprimary end points (average of
the trough values) versus dose and dose interval.
▸ Scatter plots of the coprimary end point adjusted for
covariates versus dose and dose interval with
superimposed ﬁtted linear regression models with
95% conﬁdence bands reporting:
– Log-likelihood;
– Raw output from statistical packages;
– Residual plots of each model ﬁtted.
The details of the report may evolve as the study pro-
gresses. The quorate DFC will be comprised of a statisti-
cian, physician (chair and CI) and scientist, each
member has a single vote and decisions can be reached
by a majority. The Trial Steering Committee (TSC),
comprising: an independent chairperson; the CI; the
Cambridge Clinical Trials Unit, trial coordinator; a sci-
entist and statistician with relevant experience, may be
asked to review split decisions. Prior to the DFC meet-
ings, any protocol violations will be reported to the statis-
ticians and analyses will include the whole population.
Statistical methods
This study is an exploratory study that is not designed to
formally test a hypothesis in a conﬁrmatory fashion and
so a formal power calculation is inappropriate. The
sample size of 36 is achievable within the proposed time
scale, given the recruitment rates we obtained at our
study site for DILT1D study.20 21 Statistical simulations
have estimated that 36 participants will provide valuable
information under scenarios that represent a scientiﬁc-
ally plausible and clinically relevant relationship between
dose/frequency and the three coprimary end points.
There will be four groups of participants in total, and
with the longest interval being 14 days with a maximum
duration of treatment of 98 days before an interim ana-
lysis. This will allow time to observe all four groups
within the desired total study period of 2 years. Statistical
analysis will be performed after each of the four phases
of DILfrequency and the accuracy of target prediction is
expected to increase after each round of analysis.
A tri-variate normal distribution will be assumed for
the three coprimary end points (Teff, Treg and CD25 on
Tregs). A model linking dose and dose-frequency to the
Table 1 DILfrequency treatment assignment
Learning phase
Group Dose interval Total number of doses
Number of participants
Minimal dose Maximal dose
1 14th day 5 2 2
2 10th day 5 2
3 5th day 8 2
4 2nd day 8 2 2
Confirming phase
Group Dose/interval
Number of
participants
5 Determined from analysis of learning phase data 8
6 Determined from analysis of data from all previous participants 8
7 Determined from analysis of data from all previous participants 8
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mean and covariance parameters will be developed. At
the ﬁrst interim analysis the DFC will ﬁx the numerical
values that deﬁne the target range of the primary end
point. The probability of each dose/frequency laying
within the target range set at the ﬁrst interim analysis
will be tabulated along with the parameter estimates for
all models considered, using SE and 95% CIs. The
plausibility of the modelling assumptions generated by
the study statistician will be reviewed by the DFC. In sub-
sequent cohorts the choice of dose/frequencies to allo-
cate will be determined by:
▸ Setting a minimum estimated probability of reaching
the target to allow a dose/frequency to be considered
eligible for further allocation;
▸ The ranking of the probabilities if multiple dose/fre-
quencies are eligible.
If no dose/frequencies from those observed are eli-
gible for allocation then other dose/frequencies may be
considered. The decision guidelines are to be ﬁnalised
prior to the ﬁrst interim analysis based on simulations of
the operating characteristics for a variety of scenarios.
The simulations will be updated if any of the prior
assumptions are not close to the interim values, this
includes whether a more complex model is required.
Summary statistics will be provided for all coprimary
and secondary end points, broken down by dose/fre-
quency. Any such summary must use a minimum of ﬁve
participants to ensure statistical plausibility, and any
smaller subgroups will be merged to achieve the
minimum size. Continuous variables will be summarised
using mean, SD, median, maximum and minimum; cat-
egorical and binary variables will be summarised using
frequency tables reporting in an ‘x/n (p %)’ format.
A formal statistical analysis plan will be ﬁnalised in
advance of the ﬁnal data analysis.
DISCUSSION
DILfrequency will be an open-label, sequential study
designed to estimate the optimal frequency and dose of
administration of ultra-low doses of Proleukin that is
required to maintain an increase in Tregs and an
increased Treg response, that is CD25 expression,
without expanding Teffs in patients with T1D. The sec-
ondary objective is to characterise the effects of repeated
doses of Proleukin on the immune system. For example,
a subset of NK cells express CD25 and are highly respon-
sive to IL-233 34 and we aim to analyse the effects of
Proleukin administration on this subpopulation of cells
in some detail. Our approach contrasts with a traditional
randomised, double-blind placebo-controlled trial
design used in T1D immunotherapy trials to date. In a
traditional trial design drug mechanisms, molecular
events and biomarkers can only be related to the
outcome once the results are un-blinded at the end of
the trial. Moreover, previous trials have empirically esti-
mated the dose and frequency of agents, based on
chemotherapy regimens for cancer and this may have
contributed to the limited efﬁcacy of Proleukin observed
in these trials.22 25 35 36 In our view, these analyses
should be completed before the planning and design of
further clinical testing of Proleukin for T1D therapy in
phase II and III trials.
The selection of primary end points for the
DILfrequency study has been informed by our experi-
ence in DILT1D in which a dose-dependent increase in
Tregs was observed and an increase in CD25 expression
on Tregs was found to be a sensitive and reproducible
marker of Proleukin administration (unpublished
results). It will be important to establish that repeat
dosing in DILfrequency does not lead to an increase in
Teffs. Therefore, Teffs are the third of the coprimary
end points that will be measured in DILfrequency. In
addition to the three coprimary end points, this study
will deﬁne the cellular outcome of frequent administra-
tion of Proleukin by detailed immunophenotyping,
genetic, epigenetic and transcriptional analyses of per-
ipheral blood subsets from participants before, during
and after Proleukin treatment. These exploratory assays
will be performed in order to deﬁne the mechanism of
drug action and to understand the effect of repeated
dosing of Proleukin on biomarkers.
DILfrequency challenges any pretrial assumptions
about what the ‘optimal’ dose-frequency should be, by
continuously adapting the dose-frequency after each
interim analysis. The adaptive protocol outlined here
allows for the most efﬁcient derivation of the optimum
dose-frequency and potentially, fewer participants are
required compared to an equivalent ﬁxed trial design.
Furthermore, the DILfrequency design has the ﬂexibility
to adapt to a wider range of dose frequencies of
Proleukin than could be pragmatically investigated in a
single ﬁxed-dose study. The higher number of partici-
pants at or near the optimal dose and dose-frequency in
DILfrequency improves the statistical power for analysing
mechanistic and biomarker data in addition to the infor-
mation gained by obtaining multiple measures from
each participant over time.
We propose that our approach to drug development
can be adopted widely across a range of disorders and
that it is an important foundation to a future of preci-
sion medicine.
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